Dino S. Sangiamo

Partner
Sangiamo Dino

Dino Sangiamo is a litigator who represents clients in complex pharmaceutical, mass tort, and commercial litigation. He frequently appears before U.S. federal and state courts, agencies, congressional committees, and the Office of Special Masters of the U.S. Court of Federal Claims (Vaccine Court). Dino primarily represents clients in the pharmaceutical and healthcare industries, including vaccine manufacturers and other companies, hospitals and hospital systems, medical research organizations, and organ banks. 

Dino has served as lead counsel in a variety of matters related to medical side effects, injuries, birth defects, and trade secrets. Dino often works with his clients on such matters as:

  • Developing nationwide mass tort litigation and arbitration strategies, and developing and implementing legal, factual, and scientific defenses
  • Coordinating with other industry defendants and managing company-wide discovery, including defending company officials at deposition and developing approaches to large-scale document discovery
  • Arguing cases of first impression before appellate courts
  • Research fraud matters in various contexts, including cases involving the False Claims Act (FCA)
  • Serving as local counsel in vaccine and medical device cases

Dino counsels clients on public relations activities, internal regulatory compliance programs, and client business initiatives. His practice also includes arbitration and cases involving cutting-edge medical research.

Experience

Representative Matters

Recent Pharmaceutical Practice

  • Represented a vaccine manufacturer in a whistleblower lawsuit alleging fraudulent conduct in  a clinical trial, and misstatement of a product’s efficacy
  • Represented the manufacturer of an adult vaccine in a lawsuit alleging that brain injury resulted from vaccination
  • Represented the manufacturer of an anti-epileptic drug in nationwide litigation concerning alleged birth defects from maternal use of the product
  • Represented the manufacturer of an anesthetic in nationwide litigation concerning allegations of injury from use of the product in a continuous infusion “pain pump”
  • Represented a vaccine manufacturer in nationwide litigation concerning the allegation that a preservative in vaccines causes autism
  • Represented a manufacturer of a cholesterol-reducing drug in nationwide litigation concerning allegations of muscle and psychological injuries
  • Represented a vaccine manufacturer as intervenor in defense of a lawsuit filed against the FDA for release of data previously submitted by the manufacturer to the government
  • Represented a vaccine manufacturer defending against efforts to issue subpoenas for the manufacturer’s documents in Vaccine Court
  • Represented a vaccine manufacturer in protecting its confidential commercial information and trade secrets contained in documents produced by the government, in proceedings in Vaccine Court
  • Represented a vaccine manufacturer in responding to congressional inquiries

Recent Commercial Practice

  • Represented a medical research institution in claims of research fraud
  • Represented a hospital system in an outsourcing contract dispute with a pharmaceutical re-packager
  • Represented a hospital in a dispute over construction and installation of a hyperbaric chamber
  • Represented an organ bank in a potential dispute over termination of a contract with an organ supplier
     

Insights

Credentials
+

Education

  • J.D. cum laude Harvard Law School 1989
  • B.A. Pennsylvania State University 1985

Bar Admissions

  • District of Columbia
  • Maryland

Clerk Experience

  • Honorable Francis D. Murnaghan, Jr. U.S. Court of Appeals for the Fourth Circuit 1989 - 1990

Professional Memberships and Activities

  • Member, Advisory Commission on Childhood Vaccines

Recognition
+

  • The Best Lawyers in America, Commercial Litigation, 2024
  • Who’s Who Legal, Product Liability Defense, 2017 – 2018, 2020
  • Legal 500, Dispute Resolution - Product liability, mass tort and class actions - defense: pharmaceuticals and medical devices, 2013, 2021 – 2023